<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Incannex Healthcare Ltd Adr — News on 6ix</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr</link>
<description>Latest news and press releases for Incannex Healthcare Ltd Adr on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/incannex-healthcare-ltd-adr" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683586bb78dffbe2df0fe11b.webp</url>
<title>Incannex Healthcare Ltd Adr</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr</link>
</image>
<item>
<title>Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-psx-001-program-aligns-with-white-house-executive-order-accelerating-access-to-psychedelic-treatments-for-serious-mental-illness</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-psx-001-program-aligns-with-white-house-executive-order-accelerating-access-to-psychedelic-treatments-for-serious-mental-illness</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>Company’s oral synthetic psilocybin program advances within significantly improved regulatory environmentMELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.” The Company believes its</description>
</item>
<item>
<title>Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-reactivates-share-repurchase-program-underscoring-confidence-in-valuation-and-strategic-position</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-reactivates-share-repurchase-program-underscoring-confidence-in-valuation-and-strategic-position</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days MELBOURNE, Australia and NEW YORK,</description>
</item>
<item>
<title>Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-partnership-with-the-aasm-foundation-in-support-of-sleep-apnea-research</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-partnership-with-the-aasm-foundation-in-support-of-sleep-apnea-research</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral</description>
</item>
<item>
<title>Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-highlights-strong-balance-sheet-with-approximately-dollar75-million-in-cash-and-no-debt-as-company-advances-ihl-42x-development</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-highlights-strong-balance-sheet-with-approximately-dollar75-million-in-cash-and-no-debt-as-company-advances-ihl-42x-development</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program MELBOURNE, Australia and NEW YORK, March 18, 2026</description>
</item>
<item>
<title>Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-inc-announces-pricing-of-dollar10-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-3</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-inc-announces-pricing-of-dollar10-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-3</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the “Company") a clinical-stage</description>
</item>
<item>
<title>Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-strengthens-clinical-development-pathway-for-ihl-42x-following-positive-phase-2-outcomes-1</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-strengthens-clinical-development-pathway-for-ihl-42x-following-positive-phase-2-outcomes-1</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program MELBOURNE, Australia and NEW YORK, March</description>
</item>
<item>
<title>Incannex Announces Reverse Stock Split</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-announces-reverse-stock-split</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 MELBOURNE, Australia and NEW YORK, Feb. 25, 2026</description>
</item>
<item>
<title>Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/stonegate-updates-coverage-on-incannex-healthcare-inc-ixhl-2q-2026</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/stonegate-updates-coverage-on-incannex-healthcare-inc-ixhl-2q-2026</guid>
<pubDate>Wed, 18 Feb 2026 23:35:00 GMT</pubDate>
<description>Dallas, Texas--(Newsfile Corp. - February 18, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus...</description>
</item>
<item>
<title>Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-additional-appointments-130000591</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-additional-appointments-130000591</guid>
<pubDate>Thu, 29 Jan 2026 13:00:00 GMT</pubDate>
<description>Expands clinical expertise to support disciplined advancement of the PSX-001 programMELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide i</description>
</item>
<item>
<title>Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-formation-clinical-130000200</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-announces-formation-clinical-130000200</guid>
<pubDate>Thu, 22 Jan 2026 13:00:00 GMT</pubDate>
<description>Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of developmentMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed</description>
</item>
<item>
<title>Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-wins-research-development-130000097</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-wins-research-development-130000097</guid>
<pubDate>Thu, 15 Jan 2026 13:00:00 GMT</pubDate>
<description>MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep</description>
</item>
<item>
<title>Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-delivers-transformational-2025-130000322</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-delivers-transformational-2025-130000322</guid>
<pubDate>Wed, 14 Jan 2026 13:00:00 GMT</pubDate>
<description>Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company for conti</description>
</item>
<item>
<title>Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-granted-fda-fast-track-130000359</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-granted-fda-fast-track-130000359</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA). The Fast Track designation was supported by promising safety, efficacy, and pharmac</description>
</item>
<item>
<title>Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-provides-shareholder-highlighting-clinical-120000492</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-provides-shareholder-highlighting-clinical-120000492</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growthMELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and corporate initiatives and o</description>
</item>
<item>
<title>Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-granted-180-day-extension-120000248</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-granted-180-day-extension-120000248</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>MELBOURNE, Australia and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). Incannex now has until April 20, 2026, to me</description>
</item>
<item>
<title>Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-reports-positive-results-phase-120000102</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-reports-positive-results-phase-120000102</guid>
<pubDate>Tue, 26 Aug 2025 12:00:00 GMT</pubDate>
<description>Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measures of anxiety, mood, disability, and quality of life; results establish PSX-001 as a leading psilocybin-assisted therapy in development globallyMELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly Psi-GAD), a psilocybin-a</description>
</item>
<item>
<title>Incannex Healthcare Authorizes $20 Million Share Repurchase Program</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-authorizes-20-million-120000442</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-healthcare-authorizes-20-million-120000442</guid>
<pubDate>Fri, 22 Aug 2025 12:00:00 GMT</pubDate>
<description>MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”). Under the Repurchase Program, the Compan</description>
</item>
<item>
<title>Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-receives-positive-patient-reported-120000823</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-receives-positive-patient-reported-120000823</guid>
<pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
<description>Exit interviews and clinical results reinforce strong potential for meaningful improvements in sleep quality, cognitive function, and daily lifeMELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical conditions, today announced new patient-reported outcome findings from a subset of participants in its RePOSA Phase 2 trial of IHL-42X for t</description>
</item>
<item>
<title>Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term</title>
<link>https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-confirms-strong-cash-position-120000220</link>
<guid isPermaLink="true">https://6ix.com/company/incannex-healthcare-ltd-adr/news/incannex-confirms-strong-cash-position-120000220</guid>
<pubDate>Thu, 31 Jul 2025 12:00:00 GMT</pubDate>
<description>MELBOURNE, Australia, July 31, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the market offering program (the “ATM”) in the near-term. As previously disclosed in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on July 24, 2025, the Company is under</description>
</item>
</channel>
</rss>